Author

Kirstin B. Liechty

Observed name: Kirstin Liechty

Institution: Tempus Labs (United States)

Observed institution: Tempus Labs (United States)

OpenAlex ID: A5065267707

EVEREST-2: A seamless phase 1/2 study of A2B694, a mesothelin (MSLN) logic-gated Tmod CAR T-cell therapy, in patients with solid tumors that show MSLN expression and human leukocyte antigen (HLA)-A*02 loss of heterozygosity (LOH).

2024 · Salman Rafi Punekar, J. Randolph Hecht, et al. · Journal of Clinical Oncology · 10

EVEREST-1: A seamless phase 1/2 study of A2B530, a carcinoembryonic antigen (CEA) logic-gated Tmod CAR T-cell therapy, in patients with solid tumors associated with CEA expression also exhibiting human leukocyte antigen (HLA)-A*02 loss of heterozygosity (LOH).

2024 · Julian R. Molina, Diane M. Simeone, et al. · Journal of Clinical Oncology · 5

EVEREST-1: Safety and efficacy data of A2B530, a logic-gated Tmod chimeric antigen receptor T-cell (CAR T) therapy, in patients with solid tumors associated with carcinoembryonic antigen (CEA) expression and with human leukocyte antigen (HLA) loss of heterozygosity (LOH).

2025 · Julian R. Molina, Patrick Grierson, et al. · Journal of Clinical Oncology · 4

634 EVEREST-1: A seamless phase 1/2 study of CEA logic-gated Tmod CAR T-cell therapy (A2B530) in patients with solid tumors associated with CEA expression also exhibiting HLA loss of heterozygosity (LOH)

2023 · Salman R Punekar, Theodore Welling, et al. · Regular and Young Investigator Award Abstracts · 3

Next generation sequencing (NGS) to identify relapsed gastrointestinal (GI) solid tumor patients with human leukocyte antigen (HLA) loss of heterozygosity (LOH) for future logic-gated CAR T therapy to reduce on target off tumor toxicity.

2022 · J. Randolph Randolph Hecht, Scott Kopetz, et al. · Journal of Clinical Oncology · 3

491 BASECAMP-1: an observational study to identify relapsed solid tumor patients with human leukocyte antigen (HLA) loss of heterozygosity (LOH) and leukapheresis for future CAR T-cell therapy

2021 · Julian Molina, William Go, et al. · Regular and Young Investigator Award Abstracts · 3

BASECAMP-1: Leveraging human leukocyte antigen (HLA) loss of heterozygosity (LOH) in solid tumors by next-generation sequencing (NGS) to identify patients with relapsed solid tumor for future logic-gated Tmod CAR T-cell therapy.

2022 · Diane M. Simeone, J. Randolph Hecht, et al. · Journal of Clinical Oncology · 2

BASECAMP-1 screening study: a model for efficient enrolment in precision oncology clinical trials

2026 · J Randolph Hecht, Julian R Molina, et al. · BMJ Oncology · 1

588 EVEREST-1: initial safety data from a seamless phase 1/2 study of A2B530, a logic-gated Tmod CAR T-cell therapy, in patients with solid tumors associated with CEA expression also exhibiting HLA-LOH

2024 · Patrick M Grierson, Salman R Punekar, et al. · Regular and Young Investigator Award Abstracts · 1

Improving ethnic and racial diversity in biomarker-driven clinical trials: A proof of concept with the BASECAMP-1 master prescreening study of patients with high-risk solid tumors with human leukocyte antigen-A*02 (HLA-A*02) loss of heterozygosity (LOH).

2024 · Caleb Joshua Smith, Diane M. Simeone, et al. · Journal of Clinical Oncology · 1

639 BASECAMP-1: Leveraging HLA loss of heterozygosity in solid tumors by NGS to identify patients with relapsed solid tumors for future CEA and MSLN logic-gated Tmod™ CAR T-cell therapy

2022 · Diane Simeone, Maria Pia Morelli, et al. · Regular and Young Investigator Award Abstracts · 1

GEMINI-BREAST: Evaluating minimal residual disease (MRD) through longitudinal circulating tumor DNA (ctDNA) profiling in breast malignancies.

2026 · Matthew E. Campbell, Lauren Lopez, et al. · Journal of Clinical Oncology

Recommendations for Defining Chimeric Antigen Receptor T-Cell (CAR T) Dose-Limiting Toxicities (DLTs) for Future Early-Stage CAR T Therapy Studies

2025 · Frederick L Locke, Sarah Nikiforow, et al. · Transplantation and Cellular Therapy

589 BASECAMP-1 is an efficient pre-screening study that identifies patients with HLA LOH and provides mutational, RNA-Seq, and microbiome data for precision logic-gated CAR T therapeutic trials

2024 · Julian R Molina, Diane M Simeone, et al. · Regular and Young Investigator Award Abstracts

Prospective BASECAMP-1 experience in patients with gastrointestinal (GI) cancer: Identifying patients with human leukocyte antigen (HLA) loss of heterozygosity (LOH) for a future therapeutic trial exploiting LOH as a tumor vulnerability.

2023 · J. Randolph Hecht, Scott Kopetz, et al. · Journal of Clinical Oncology

Works count: 15

Citation count: 34

H-index: 3

I10-index: 1